Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals.
Clinical Benefit
| Substantial |
The actual benefit of MIRCERA is substantial. |
Clinical Added Value
| no clinical added value |
MIRCERA offers no improvement in actual benefit (level V) compared to the other
erythropoiesis-stimulating agents that are indicated in the correction of anaemia associated with chronic kidney disease. |
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
wNJbf9QDCSpEbX7c
